CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: August-29-08
Credit Expiration Date: August-31-09


Presenter & Discussion Moderator

Susan C. Pannullo, MD
Director of Neuro-Oncology
Department of Neurological Surgery
Weil Cornell Medical College
Cornell University
New York, NY

Discussion Participants

Arnab Chakravarti, MD
Associate Professor of Radiation Oncology
Massachusetts General Hospital
Harvard Medical School
Boston, MA

Michael Vogelbaum, MD, PhD
Associate Director
Neurosurgical Oncology
Brain Tumor Institute
Cleveland Clinic
Cleveland, OH

Credit Hours

Physician CME: 1.0


Online Presentation

Program Description


Physicians managing patients with recurring glioma face differing and even more somber challenges than with primary glioma or metastatic tumor patients. Patients whose tumors have recurred are not naïve to many available chemotherapies and may have reached a maximal lifetime exposure to radiation therapy. This limits the clinician’s treatment options, necessitating novel or investigational approaches. There is also no consensus on what constitutes a valid endpoint once a regimen is selected, nor is there agreement about how tumor recurrence should be defined and measured. A growing momentum for the acceptance of progression-free survival is being advocated as a truer standard of determining progress than more traditional endpoints of overall survival.

Program Developer/Facilitator


Target Audience

This educational activity is designed to meet the needs of neuro-oncologists, neurosurgeons, radiation oncologists, and medical oncologists interested in the treatment of primary gliomas.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Describe the benefits and limitations of currently available salvage strategies.
  2. Explain the rationale for using progression-free survival compared to overall survival as a valid endpoint in recurrent glioma.
  3. Analyze the various criteria currently used for determining disease progression.
  4. Discuss the potential benefit of investigational and targeted therapies for recurrent high-grade glioma.


It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

This educational activity may contain discussion of published and/or investigational uses of pharmacologic agents. Some uses may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Faculty are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices in their presentations.

Dr. Chakravarti indicates he has no actual or potential conflict of interest.

Dr. Pannullo discloses that she has received research funds from Cytec, Genentech, MGI Pharma, Novocare, and NTI Pharmaceuticals. She is also on speakers' bureaus for MGI Pharma and Schering-Plough.

Dr. Vogelbaum discloses that he has received consultant fees from Genentech, MGI Pharma, and Schering-Plough.

Credit Statements

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH, Inc. and Medical Communications Media, Incorporated. AKH, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

AKH, Inc. designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Commercial Support Statements

Supported through an educational grant from Schering-Plough.


  1. Please turn off all pop-up blockers and click on the "Start Program" icon at the bottom of the page. If you have not previously registered with this website, you will be taken to the login/registration page where you will be able to register as a new member. If you have previously registered, you will be asked to verify or correct existing registration information. When ready, click on the "Start Program" icon.
  2. The next screen will be a brief pre-program survey. Please complete the survey and click on the "Done" button on the bottom of the page. Please wait while you are connected to the video server. This program, roundtable session, post-test, and evaluation will take approximately 60 minutes to complete.
  3. Instructions for completing and submitting the post-test are provided on the post-test screen. A minimum score of 70% on the post-test is required for a CME certificate. One retake is permitted.

Certificate Fee



©2008 Medical Communications Media, Inc. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational program are those of the presenters and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., or Schering-Plough Corporation. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other healthcare professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu